Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension (2022)
- Authors:
- Autor USP: SOUZA, ROGÉRIO DE - FM
- Unidade: FM
- DOI: 10.1007/s12325-022-02199-x
- Subjects: ESTUDOS RANDOMIZADOS; HIPERTENSÃO PULMONAR; TERAPIA COMBINADA; SOBREVIDA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Advances in therapy
- ISSN: 0741-238X
- Volume/Número/Paginação/Ano: v. 39, n. 9, p. 4374-4390, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: cc-by-nc
-
ABNT
SOUZA, Rogerio de et al. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Advances in therapy, v. 39, n. 9, p. 4374-4390, 2022Tradução . . Disponível em: https://doi.org/10.1007/s12325-022-02199-x. Acesso em: 31 maio 2024. -
APA
Souza, R. de, Delcroix, M., Galie, N., Jansa, P., Mehta, S., Pulido, T., et al. (2022). Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Advances in therapy, 39( 9), 4374-4390. doi:10.1007/s12325-022-02199-x -
NLM
Souza R de, Delcroix M, Galie N, Jansa P, Mehta S, Pulido T, Rubin L, Sastry BKS, Simonneau G, Sitbon O. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension [Internet]. Advances in therapy. 2022 ; 39( 9): 4374-4390.[citado 2024 maio 31 ] Available from: https://doi.org/10.1007/s12325-022-02199-x -
Vancouver
Souza R de, Delcroix M, Galie N, Jansa P, Mehta S, Pulido T, Rubin L, Sastry BKS, Simonneau G, Sitbon O. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension [Internet]. Advances in therapy. 2022 ; 39( 9): 4374-4390.[citado 2024 maio 31 ] Available from: https://doi.org/10.1007/s12325-022-02199-x - Atualização em hipertensão arterial pulmonar
- Validação de um protocolo para o teste de caminhada de seis minutos em esteira para avaliação de pacientes com hipertensão arterial pulmonar
- Chronic thromboembolic pulmonary hypertension: diagnostic limitations
- TEP com instabilidade hemodinâmica
- Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
- Carbon monoxide diffusing capacity and the complexity of diagnosis in pulmonary arterial hypertension [Editorial]
- Management of Pulmonary Arterial Hypertension
- Results of an expert consensus survey on the treatment of pulmonary arterial hypertension with oral prostacyclin pathway agents
- Pulmonary hypertension in sickle cell disease
- Building the Future of Trial Design in PAH on Solid Ground
Informações sobre o DOI: 10.1007/s12325-022-02199-x (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
